Capecitabine, Cyclophosphamide — Competitive Intelligence Brief

Capecitabine, Cyclophosphamide (Capecitabine, Cyclophosphamide) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antineoplastic. Area: Oncology.

phase 2 Antineoplastic Thymidylate synthase, DNA Oncology Small molecule

Target snapshot

Capecitabine, Cyclophosphamide (Capecitabine, Cyclophosphamide) — Vastra Gotaland Region. Capecitabine is a prodrug that is converted into 5-fluorouracil, which interferes with DNA synthesis, thereby inhibiting cancer cell growth. Cyclophosphamide is an alkylating agent that attaches an alkyl group to the DNA of cancer cells, thereby interfering with their replication.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Capecitabine, Cyclophosphamide TARGET	Capecitabine, Cyclophosphamide	Vastra Gotaland Region	phase 2	Antineoplastic	Thymidylate synthase, DNA
S-1 plus Cisplatin	S-1 plus Cisplatin	Taiho Pharmaceutical Co., Ltd.	phase 3	Antineoplastic agents	Thymidylate synthase, DNA
FOLFOXIRI with bevacizumab	FOLFOXIRI with bevacizumab	Dutch Colorectal Cancer Group	phase 3	Chemotherapy combination with anti-angiogenic monoclonal antibody	VEGF (bevacizumab component); topoisomerase I, thymidylate synthase, DNA (FOLFOXIRI components)
Placebo、CAPOX	Placebo、CAPOX	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	phase 3	chemotherapy regimen	thymidylate synthase, DNA repair enzymes
Liposomal doxorubicin hydrochloride	Liposomal doxorubicin hydrochloride	Cephalon, Inc.	marketed	Antineoplastic agent	DNA and topoisomerase II
cetuximab + cisplatin + vinorelbine	cetuximab + cisplatin + vinorelbine	Merck KGaA, Darmstadt, Germany	phase 3	Antineoplastic agents	EGFR
Trifluridine/tipiracil + bevacizumab	Trifluridine/tipiracil + bevacizumab	Second Affiliated Hospital, School of Medicine, Zhejiang University	phase 3	Antineoplastic	VEGF-A

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antineoplastic class)

1. Iwate Medical University · 1 drug in this class
2. Jiangsu Simcere Pharmaceutical Co., Ltd. · 1 drug in this class
3. Second Affiliated Hospital, School of Medicine, Zhejiang University · 1 drug in this class
4. Vastra Gotaland Region · 1 drug in this class